<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478280</url>
  </required_header>
  <id_info>
    <org_study_id>PsoPET2</org_study_id>
    <nct_id>NCT03478280</nct_id>
  </id_info>
  <brief_title>Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis</brief_title>
  <official_title>Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab&#xD;
      monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with&#xD;
      moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomised, double-blind, placebo-controlled, trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The aortic wall inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The average of maximum TBR values (MeanTBRmax) of the entire aorta at baseline and at week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The splenic inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The spleen-to-liver ratio (SLR) based on splenic and liver mean standardised uptake values (SUVmean)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The aortic wall subsegment inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The average of maximum TBR values (MeanTBRmax) of the ascending, aortic arch, descending, suprarenal, and infrarenal aorta at baseline and at week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The skin inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Severity of psoriasis measured by PASI score at baseline and at week 16</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Brodalumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brodalumab</intervention_name>
    <description>Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period</description>
    <arm_group_label>Brodalumab</arm_group_label>
    <other_name>Kyntheum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from the subject prior to performing any&#xD;
             protocol-related procedures.&#xD;
&#xD;
          2. Age 40 and above.&#xD;
&#xD;
          3. Diagnosis of chronic plaque psoriasis confirmed by a dermatologist&#xD;
&#xD;
          4. PASI ≥ 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-Danish speaking&#xD;
&#xD;
          2. Known or suspected allergy or reaction to any component of the IMP formulation.&#xD;
&#xD;
          3. History of inflammatory bowel disease, arthritis (not including psoriatic arthritis),&#xD;
             systemic lupus erythematosus, and active inflammatory skin diseases.&#xD;
&#xD;
          4. A history of malignancies within the past five years (excluding localized non-melanoma&#xD;
             skin cancer).&#xD;
&#xD;
          5. Topical corticosteroid treatment (class III or stronger) and/or ultraviolet type B&#xD;
             phototherapy within 2 weeks prior to randomization&#xD;
&#xD;
          6. Treatment with psoralen plus ultraviolet type A photochemotherapy, methotrexate,&#xD;
             cyclosporine, acitretin, or fumaric acid esters within 4 weeks prior to randomization.&#xD;
&#xD;
          7. Treatment with adalimumab, etanercept, infliximab, cosentyx, or ixekizumab within 12&#xD;
             weeks, ustekinumab within 24 weeks, or other immunosuppressive or anti-inflammatory&#xD;
             agents within 5 half-lives of the active substance prior to the FDG-PET/CT,&#xD;
             respectively.&#xD;
&#xD;
          8. Scheduled surgery during the trial period (expect minor minimally invasive&#xD;
             procedures).&#xD;
&#xD;
          9. Systemic infection or fever within 7 days prior to FDG-PET/CT.&#xD;
&#xD;
         10. Severe obesity (&gt; 150 kg due to a PET/CT scanner limitation).&#xD;
&#xD;
         11. Presence of uncontrolled diabetes mellitus (HbA1c &gt; 75 mmol/mol and/or blood sugar &gt;&#xD;
             11.1 mmol/l and/or clinical judgment).&#xD;
&#xD;
         12. History of coagulation defects (clinical judgment).&#xD;
&#xD;
         13. Active or latent tuberculosis requiring treatment.&#xD;
&#xD;
         14. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),&#xD;
             hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at&#xD;
             screening. Subjects with positive HBsAb may be randomised provided they are hepatitis&#xD;
             B vaccinated and have negative HBsAg and HBcAb.&#xD;
&#xD;
         15. History of any known primary immunodeficiency disorder including a positive human&#xD;
             immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral&#xD;
             medications as determined by medical history and/or subject's verbal report.&#xD;
&#xD;
         16. No history of varicella zoster infection and negative varicella antibody test (until&#xD;
             varicella vaccination is completed).&#xD;
&#xD;
         17. History of chronic alcohol or drug abuse within 12 months prior to screening, or any&#xD;
             condition associated with poor compliance as judged by the investigator.&#xD;
&#xD;
         18. History of intravenous drug use.&#xD;
&#xD;
         19. History of attempted suicide or is at significant risk of suicide.&#xD;
&#xD;
         20. Major surgery within the past 3 months.&#xD;
&#xD;
         21. Pregnancy or lactation (Women of childbearing potential must use a highly effective*&#xD;
             form of birth control (confirmed by the investigator) throughout the trial and until&#xD;
             12 weeks after discontinuation of treatment with brodalumab.&#xD;
&#xD;
         22. Claustrophobia.&#xD;
&#xD;
         23. Reduced renal function (serum creatinine &gt; 200 μmol/L or cr-EDTA clearance &lt; 30&#xD;
             ml/min)&#xD;
&#xD;
         24. Any disorder, including but not limited to, cardiovascular, lung, gastrointestinal,&#xD;
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,&#xD;
             haematological, immunological, psychiatric, or major physical impairment that is not&#xD;
             stable, in the opinion of the investigator, and could:&#xD;
&#xD;
               -  Affect the safety of the subject throughout the trial.&#xD;
&#xD;
               -  Influence the findings of the trial or their interpretations.&#xD;
&#xD;
               -  Impede the subject's ability to complete the entire duration of trial.&#xD;
&#xD;
                    -  A highly effective method of birth control is defined as one which results&#xD;
                       in a low failure rate (less than 1% per year) such as bilateral tubal&#xD;
                       occlusion, intrauterine device (IUD), intrauterine hormone-releasing system&#xD;
                       (IUS), combined (estrogen and progestogen containing) hormonal contraception&#xD;
                       associated with inhibition of ovulation (oral, intravaginal, transdermal),&#xD;
                       progestogen-only hormonal contraception associated with inhibition of&#xD;
                       ovulation (oral, injectable, implantable), sexual abstinence (when this is&#xD;
                       in line with the preferred and usual life style of the subject),&#xD;
                       vasectomised partner (given that the subject is monogamous). The subjects&#xD;
                       must have used the contraceptive method continuously for at least 1 month&#xD;
                       prior to the pregnancy test. A female is defined as not being of child&#xD;
                       bearing potential if she is postmenopausal (at least 12 months with no&#xD;
                       menses without an alternative medical cause prior to screening), or&#xD;
                       surgically sterile (hysterectomy, bilateral salpingectomy or bilateral&#xD;
                       oophorectomy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Bregnhøj, MD, PhD</last_name>
    <phone>+45 2183 5720</phone>
    <email>annebreg@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bregnhøj, PhD</last_name>
      <email>annebreg@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Bregnhøj</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brodalumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03478280/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

